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Introduction
Multicentric Castleman’s disease (MCD) is a rare, non-
clonal lymphoproliferative disorder characterized by
constitutional symptoms, anaemia and generalised
lymphadenopathy.
Aim
The present study intends to compare demographic fea-
tures, clinical presentation, laboratory studies, imaging
results as well as treatment regimens and out- come in
our MCD patients to those of larger reported series.
Method
We reviewed the files of 930 HIV-1-infected patients
from our AIDS Reference Centre. Data was collected
from the operating software for the patients’ medical
records of our institution.
Results
We report a series of five cases of MCD among our
HIV/AIDS patients’ cohort. Three were of African ori-
gin. They were diagnosed after 2003, after a mean dura-
tion of 85 months of HIV-seropositivity. All presented
with characteristic clinical features and laboratory find-
ings (table 1), and all but one patient were started on
HAART only a few months before or upon MCD diag-
nosis. Four patients were treated with chemotherapy,
and one with HAART only. One patient who was given
Adriamycin/Bleomycin/Vinblastin is in continuous
remission after 6 years of follow-up. Two are alive, with
good symptom control, regardless of the treatment they
received. One recently relapsed, and one unfortunately
died before completing the intended 6-courses che-
motherapy regimen.
Conclusion
MCD is a rare, but rising issue among HIV-infected
patients. The clinical and paraclinical features of our
series of five patients are in keeping with those of larger
reported series. Currently, treatment is mainly che-
motherapy-based, but a wide variety of protocols have
been used, mainly because of the lack of available evi-
dence. New approaches such as anti-CD 20 antibodies
seem highly effective, and the role of HHV-8 needs to
be further investigated, as it might be an important tar-
get for future treatment.
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